Gene-guided gout treatment for safer, effective care
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests whether a genetic test can help doctors choose the safest and most effective gout medication. It aims to prevent severe allergic reactions by personalizing treatment based on your genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a doctor-confirmed diagnosis of gout.
- You must be ready to start a medication to lower uric acid (urate-lowering therapy) and have never taken allopurinol before.
- You must be willing to attend follow-up visits at 1, 3, 6, and 12 months.
- You must not have severe kidney disease requiring dialysis or a kidney transplant.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational tablet called BR2251 to see if it can lower uric acid levels in people with gout and hyperuricemia (too much uric acid in the blood). If you qualify, you may get a new treatment that could help prevent painful gout attacks.
This study tests whether using a smartphone or tablet to monitor your gout from home can help manage the condition. You may qualify if you have had at least one gout flare in the last year and have high uric acid levels.
This study compares two different treatment goals for a blood level called urate in people with gout. The goal is to see which approach lowers gout flares better while helping people feel better.
This study looks at whether people with gout whose uric acid is well controlled and whose joints are clear on ultrasound can safely stop their daily uric acid-lowering medication. Participants are randomly assigned to either continue their current medication or stop it, and their health is monitored to see if stopping leads to gout flares or joint damage.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
This trial tests if gradually lowering the dose of the gout medication febuxostat is safe for people whose gout has been well-controlled for at least 5 years. The goal is to see if a lower dose can still keep uric acid levels in a healthy range.
Hear when a new Gout Initiating Urate-loweringUrate-lowering Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.